Faculty & Staff Scholarship
2015

In Vitro Selection of a Single-Stranded DNA Molecular Recognition
Element against Clostridium difficile Toxin B and Sensitive
Detection in Human Fecal Matter
Ka L. Hong
Eamonn Maher
Ryan M. Williams
Letha J. Sooter

Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications

Hindawi Publishing Corporation
Journal of Nucleic Acids
Volume 2015, Article ID 808495, 12 pages
http://dx.doi.org/10.1155/2015/808495

Research Article
In Vitro Selection of a Single-Stranded DNA Molecular
Recognition Element against Clostridium difficile Toxin B and
Sensitive Detection in Human Fecal Matter
Ka Lok Hong,1 Eamonn Maher,1 Ryan M. Williams,1,2 and Letha J. Sooter1
1

Department of Basic Pharmaceutical Sciences, West Virginia University, 1 Medical Center Drive, P.O. Box 9530,
Morgantown, WV 20506, USA
2
Molecular Pharmacology & Chemistry Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue,
New York, NY 10065, USA
Correspondence should be addressed to Letha J. Sooter; lsooter@hsc.wvu.edu
Received 18 November 2014; Revised 14 January 2015; Accepted 19 January 2015
Academic Editor: Ben Berkhout
Copyright © 2015 Ka Lok Hong et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Toxin B is one of the major virulence factors of Clostridium difficile, a bacterium that is responsible for a significant number of
diarrhea cases in acute care settings. Due to the prevalence of C. difficile induced diarrhea, rapid and correct diagnosis is crucial
in the disease management. In this study, we have employed a stringent in vitro selection method to identify single-stranded DNA
molecular recognition elements (MRE) specific for toxin B. At the end of the 12-round selection, one MRE with high affinity (𝐾𝑑 =
47.3 nM) for toxin B was identified. The selected MRE demonstrated low cross binding activities on negative targets: bovine serum
albumin, Staphylococcus aureus alpha toxin, Pseudomonas aeruginosa exotoxin A, and cholera toxin of Vibrio cholera. A modified
sandwich ELISA assay was developed utilizing the selected ssDNA MRE as the antigen capturing element and achieved a sensitive
detection of 50 nM of toxin B in human fecal preparations.

1. Introduction
Toxin B is a virulence factor secreted by Clostridium difficile,
an obligate anaerobic, spore-forming, Gram-positive bacillus
bacterium [1]. Clostridium difficile induced diarrhea accounts
for more than 300,000 or almost 30% of all cases of diarrhea
in acute care settings [2, 3]. It also causes prolonged hospital
stays and therefore increased cost burden in the health care
system [4]. It has been reported that the cost of C. difficile
infections is between $436 million and $3.2 billion per year
in the USA [4, 5]. In addition to economic burdens, the
mortality rates of C. difficile infections have also increased
from 5.7 per million in 1999 to 23.7 per million in 2004 [6].
C. difficile produces two major exotoxins: toxin A and
toxin B. Toxin B has been shown to be 1000 times more toxic
than toxin A. While both toxins are considered to be the cause
of C. difficile colitis, all toxin-producing strains of C. difficile
produce toxin B [7]. Upon colonization of toxic strains
of C. difficile in the colon, the produced toxins deactivate
GTPases, such as Rho and Rac, disrupt cytoskeleton and

signal transductions, and result in cell rounding and loss of
cell structures, leading to host inflammatory responses [8].
Due to the problems associated with C. difficile infection
(CDI), early and accurate diagnosis is important for disease
management and patient survival [9]. Currently, diagnostic
tests for CDI are stool culturing, cell cytotoxicity neutralization assay, enzyme immunoassay (EIA) for toxins A and
B, detection of C. difficile glutamate dehydrogenase (GDH),
and polymerase chain reaction (PCR) detection of C. difficile
genes [10]. Culturing diagnosis is very sensitive, but the
turnaround time can be up to 3–5 days [11]. GDH testing
is very sensitive but is not specific and requires additional
EIA for toxin A and/or toxin B [11, 12]. There are multiple
commercial EIA kits for toxin A/B detection on the market,
but their sensitivities vary and they may not be available in
all countries [13]. PCR test has a rapid turnaround with good
sensitivity and specificity but does not detect the presence
of virulence factors and the cost associated with the test
may limit its usage [11, 14]. A confirmed diagnosis of CDI
usually requires positive results from two or three of the
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Figure 1: Illustration of the SELEX process. The SELEX process begins with 1015 ssDNA molecules and incubation with the target toxin B.
Those that bind to toxin B are amplified and subsequently incubated with negative targets. Those that do not bind to negative targets are
retained and amplified, thus completing one round of in vitro selection.

available tests [15, 16]. When the results of these tests are
combined, they are sensitive and specific, but excessive cost
and turnaround time are major drawbacks. Therefore, it is
important to identify new diagnostic techniques that can
address some of these limitations.
One potential method of addressing problems associated with toxin B testing is through molecular recognition
and detection. Molecular recognition elements (MREs) are
defined to have high specificity and affinity toward user
defined targets. Molecules such as single-stranded oligonucleotides, small peptides, antibody fragments, and full length
antibodies can all participate in molecular recognition and
have been studied in different types of biosensors [17–20].
MREs are identified by an in vitro selection process called
systematic evolution of ligands by exponential enrichment
(SELEX), which was first described by the Gold laboratory
in 1990 [21]. Nucleic acid MREs are usually selected from a
large random library consisting of 1013 to 1015 different singlestranded DNA (ssDNA) or RNA molecules. The library is
enriched through repeated cycles of incubation with the
desired target and subsequent removal of molecules that bind
to undesired targets. At the end of the selection process, the
diversity of the MRE library is decreased to the point that one
or a few candidate MREs can be identified for affinity and
specificity screening against the target of interest.
In this study, we applied a stringent SELEX scheme to
obtain a ssDNA MRE that binds to toxin B with high affinity

and specificity [22–24]. The selection scheme was designed
to eliminate MREs that bind to negative targets that are likely
to coexist in the target environment. Bovine serum albumin
(BSA) was chosen to be the first negative target based on
its similarity to human serum albumin and its prevalence
as a blocking agent in assay applications [25]. Alpha toxin
of Staphylococcus aureus and exotoxin A of Pseudomonas
aeruginosa are virulence factors of common nosocomial
infections, which have the likelihood to coinfect hospitalized
patients [26–28]. Cholera toxin of Vibrio cholerae is the
causative agent of cholera induced watery diarrhea, which
symptomatically mimics CDI [29]. In addition to the selection and characterization of the toxin B-specific ssDNA MRE,
a modified enzyme-linked immunoassay (ELISA) has been
developed which utilizes the identified ssDNA MRE. The
assay was able to show the detection of toxin B in human
fecal samples at nanomolar concentrations. This work shows
the potential of using ssDNA MREs in diagnostic applications
[30–32].

2. Materials and Methods
2.1. In Vitro Selection of Toxin B-Specific MREs. The selection
process began with a single-stranded DNA (ssDNA) library
consisting of 1015 different molecules designed by our laboratory as previously described (Figure 1) [22]. In brief, the
library, termed RMW.N34, consists of two 23-base constant
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regions for polymerase chain reaction (PCR) amplification
flanking a 34-base random region (commercially synthesized
by Eurofins MWG Operon; Huntsville, AL, USA). A total
of 12 rounds of SELEX were performed (Table 1) to identify
ssDNA molecules that bound specifically to toxin B and not
to negative targets (Figure 2).
Lyophilized toxin B (List Biological Laboratories; Campbell, CA, USA) was reconstituted in pure water and covalently
immobilized to carboxylic acid-coated magnetic beads (Dynabeads M-270 carboxylic acid) (Life Technologies; Grand
Island, NY, USA) via an amidation reaction using Nhydroxysulfonyl succinimide (sulfo-NHS) (Pierce; Rockford,
IL, USA) and 1-ethyl-3-(3-dimethylaminopropyl) (EDC)
(Pierce; Rockford, IL, USA) according to manufacturer’s
protocol.
For positive rounds, 6 𝜇L of immobilized target was
incubated with ssDNA library in 200 𝜇L of selection buffer
composed of 100 mM sodium chloride, 20 mM Tris-HCl,
and 2 mM magnesium chloride (1x selection buffer, SB) at
room temperature with rotation (8 RPM). After incubation,
the immobilized target and solution were separated using
a magnet. Unbound ssDNA in solution was removed.
Immobilized target/DNA complexes were washed three
times with 200 𝜇L of SB and resuspended in 100 𝜇L of SB.
This bound DNA served as a template for PCR amplification.
The PCR conditions were as follows: bound ssDNA, 400 nM
forward and biotinylated reverse RMW.N34 primers (Eurofins MWG Operon; Huntsville, AL) (forward: 5 -TGTACCGTCTGAGCGATTCGTAC-3 , biotinylated reverse:
5 -biotin-GCACTCCTTAACACTGACTGGCT-3 ), 250 𝜇M
deoxynucleotide triphosphates, 1x GoTaq reaction buffer
(Promega; Madison, WI, USA), 3.5 units Taq polymerase,
and pure water. Thermal cycling conditions were as follows:
denature at 95∘ C for 5 minutes; cycle at 95∘ C for 1 minute,
63∘ C for 45 seconds, and 72∘ C for 1 minute; and final
extension temperature at 72∘ C for 7 minutes [22]. A largescale 3 mL amplification was carried out after each round of
positive and negative selection. This selection procedure for
the immobilized toxin B target was performed for rounds
1–6, each with decreasing incubation time.
After PCR amplification, amplified dsDNA was purified
with the IBI PCR purification kit (IBI Scientific; Peosta,
IA, USA) according to the manufacturer’s protocol. Eluted
dsDNA containing the biotinylated reverse strand was subjected to single-strand separation and ethanol precipitation
of the forward strand as previously described [22]. This
procedure was performed after each positive and negative
round of selection.
For negative rounds, multiple negative targets were covalently immobilized to carboxylic acid-coated magnetic beads
as described above. Immobilized negative targets were incubated with the enriched ssDNA library in the same conditions
as positive rounds. However, after magnetic separation,
unbounded ssDNA in solution was used as template for
PCR amplification. This selection procedure for immobilized
negative targets was performed for rounds 2–6.
Competitive elution with free toxin B in solution was performed beginning in round 7 positive. The enriched ssDNA
library was first incubated with immobilized toxin B as
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described above. After magnetic separation and washes, toxin
B at a concentration of 20 𝜇g/mL in 100 𝜇L of 1x SB was added
to magnetic beads and incubated for 5 minutes and then
subjected to magnetic separation. The solution containing
ssDNA bound to free toxin B served as PCR template. This
procedure was performed for rounds 7–12 positive, each with
decreasing time of incubation and target concentrations.
Similarly, competitive elution with negative targets in
solution was performed beginning in round 7 negative as
outlined above. However, ssDNA molecules bound to the
immobilized target were resuspended in 100 𝜇L of 1x selection
buffer and served as PCR template. This procedure was
performed for rounds 7–11 negative.
2.2. Cloning and Sequencing of Toxin B-Specific MREs. In
order to analyze the ssDNA library for consensus binding
sequences, the library was cloned and sequenced following
rounds 3 negative, 6 negative, 9 negative, and 12 positive.
Identical procedures were performed as previously described
[22]. In brief, the library was amplified with nonbiotinylated
primers, and the fresh PCR product was ligated into the
pCRII vector (Invitrogen; Carlsbad, CA, USA) and cloned
into competent E. coli according to the manufacturer’s protocol. The cloned plasmid was extracted and purified with
AxyPrep Plasmid Miniprep kit (Axygen; Union City, CA,
USA) and subsequently sequenced with the M13R primer by
commercial source (Eurofins MWG Operon). A total of 30–
80 randomly selected clones were sequenced and analyzed.
2.3. Toxin-Specific MRE Sequence Alignment and Analysis.
Sequences were first grouped into superfamilies by analyzing common tetranucleotide sequences from the variable
regions of sequenced clones. The largest superfamily was then
chosen for alignment and divided into smaller subfamilies.
All sequences in the subfamilies were analyzed for their
predicted secondary structures, the predicted Gibbs free
energy values of those structures, and the percent homology.
These parameters were considered in the choice of candidate
sequences.
2.4. Toxin B MRE Binding Assays with Surface Plasmon
Resonance. One candidate sequence from the round 12
library was chosen for further characterization. The candidate
sequence was designated as R12.69. The secondary structure
was predicted by the Mfold DNA web server using the following conditions: 25∘ C, 100 mM Na+ , and 2 mM Mg2+ [33].
Commercially synthesized 5 -amino-C6 modified R12.69 (5 amino-C6 indicates a primary amino group attached to the 5
end of the oligonucleotide with a six-carbon spacer between
the two) (Eurofins MWG Operon; Huntsville, AL, USA) was
used for surface plasmon resonance (SPR) affinity assays.
Both in-house produced and commercially purchased CM5
(GE Healthcare; Piscataway, NJ, USA) SPR sensor chips were
used for binding assays.
Home-made gold chips were fabricated from glass slides
(12 mm × 10 mm) coated with a 2 nm titanium adhesion
layer and a 45 nm gold layer. Metals were deposited using a
Temescal BJD-2000 system (Edwards Vacuum; Phoenix, AZ)

Positive selection
Immobilized target (IT)
IT
IT
IT
IT
IT
IT/competitive elution with 20 𝜇g/mL free toxin B
IT/competitive elution with 20 𝜇g/mL free toxin B
IT/competitive elution with 10 𝜇g/mL free toxin B
IT/competitive elution with 5 𝜇g/mL free toxin B
IT/competitive elution with 2.5 𝜇g/mL free toxin B
IT/competitive elution with 1 𝜇g/mL free toxin B

Time
24 hrs
18 hrs
13 hrs
7 hrs
3 hrs
30 min
5 min/5 min
5 sec/5 sec
5 sec/5 sec
5 sec/5 sec
5 sec/5 sec
5 sec/5 sec

Negative selection
—
BSA INT
BSA INT
Exotoxin A INT
Exotoxin A INT
BSA INT
IT/competitive elution with 20 𝜇g/mL free BSA
IT/competitive elution with 20 𝜇g/mL free alpha toxin, 1 hour
IT/competitive elution with 20 𝜇g/mL free cholera toxin, 1 hour
IT/competitive elution with 20 𝜇g/mL free exotoxin A, 1 hour
IT/competitive elution with 20 𝜇g/mL free BSA, 24 hrs
—

Time
—
22 hrs
26 hrs
22 hrs
26 hrs
24 hrs
5 min/5 min
5 sec/1 hrs
5 sec/1 hrs
5 sec/1 hrs
5 sec/24 hrs

In vitro selection performed for identifying toxin B-specific MRE. Immobilized target (IT) is toxin B conjugated to magnetic beads. Immobilized negative target (INT) is negative targets conjugated to magnetic
beads. BSA is the abbreviation for bovine serum albumin. Times listed are incubation times in hours (hrs), minutes (min), or seconds (sec).

Round
1
2
3
4
5
6
7
8
9
10
11
12

Table 1: Systematic evolution of ligands by exponential enrichments (SELEX) scheme for toxin B-specific MRE selection.
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(a) Toxin B

(b) Exotoxin A

(c) Bovine serum albumin

(d) Cholera toxin

(e) Alpha toxin

Figure 2: Structures of targets used in the SELEX scheme and cross binding assays. (a) Ribbon structure of the selection target, Clostridium
difficile toxin B (PDB 2BVM, 270 kDa) [54]. ((b), (c), (d), and (e)) Ribbon structure of Pseudomonas aeruginosa exotoxin A (PDB 1IKQ,
66 kDa) [55], bovine serum albumin (PDB 4F5S, 66.5 kDa) [56], Vibrio cholerae cholera toxin (PDB 2A5D, 84 kDa) [57], and Staphylococcus
aureus alpha toxin (PDB 3ANZ, 33 kDa) [58], used in negative rounds of selection and cross binding assays.
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with an Inficon XTC/2 deposition controller (East Syracuse,
NY). The home-made gold chips were first cleaned in 100%
ethanol under sonication for 5 minutes and then immersed
in a solution of 10 mM 11-mercaptoundecanoic acid (11MUA) (Sigma; St. Louis, MO) and 10 mM triethylene glycol
mono-11-mercaptoundecylether (PEG3) (Sigma) in a 1 to 5
ratio overnight under argon for the formation of the selfassembled monolayer. Subsequently, gold chips were rinsed
in 100% ethanol and pure water, blown dry with nitrogen, and
assembled onto carrying cartridges for SPR binding assays
using a Biacore X100 (GE Healthcare; Piscataway, NJ, USA).
Both in-house produced and CM5 purchased SPR sensor
chips were activated by injecting 100 mM N-hydroxysulfonyl
succinimide (sulfo-NHS) (Pierce; Rockford, IL, USA) and
400 mM 1-ethyl-3-(3-dimethylaminopropyl) (EDC) (Pierce;
Rockford, IL, USA) at a 1 to 1 ratio to both active (flow cell 2)
and reference (flow cell 1) flow cells at a flow rate of 5 𝜇L/min
for ten minutes. An immobilization buffer composed of
100 mM sodium chloride, 20 mM potassium phosphate, and
2 mM magnesium chloride, pH 7.4, was used as the running
buffer. Then, 300 𝜇L of 100 nM 5 -amino-C6 modified R12.69
in immobilization buffer was injected into the active flow cell
at a flow rate of 5 𝜇L/min, followed by 10-minute injection of
1 M ethanolamine-HCl pH 8.5 into both active and reference
flow cells in order to inactivate unreacted sensor surface.
Maximum levels of immobilization were obtained for affinity
analyses.
Single cycle kinetics assays were performed to determine
the affinity of R12.69 to toxin B. The 1x selection buffer was
used as running buffer during kinetics assays. Toxin B at
various concentrations (20 nM, 40 nM, 60 nM, 100 nM, and
200 nM) in 1x SB was injected into both flow cells at a flow rate
of 30 𝜇L/min for 120 seconds with a dissociation time of 150
seconds. Control and baseline adjusted sensorgram responses
were analyzed with the Biacore X100 evaluation software (GE
Healthcare; Piscataway, NJ, USA). A 1 : 1 kinetics model was
used to determine the equilibrium dissociation constant (𝐾𝑑 ).
This binding assay was performed in triplicate.
2.5. Toxin B Fluorescence Cross Binding Assays. To determine the cross binding activities of the selected MRE,
5 FAM modified R12.69 was purchased from Eurofins MWG
Operon. The assay was performed as previously described
with slight modifications [34]. Toxin B, exotoxin A (List
Biological Laboratories; Campbell, CA, USA), alpha toxin
(List Biological Laboratories; Campbell, CA, USA), cholera
toxin (List Biological Laboratories; Campbell, CA, USA),
and BSA at 40 nM in 90 𝜇L of 50 mM carbonate/bicarbonate
buffer (pH 9.6) were added into individual wells of a 96-well
Nunc C8 LockWell MaxiSorp microplate (Pierce; Rockford,
IL, USA). Wells containing 1x SB with 0.05% Tween-20 served
as the negative background control. The plate was placed
on a shaker and incubated at 4∘ C overnight for protein
coating (500 RPM). Subsequently, wells were blocked with
90 𝜇L of 1x SB with 0.05% Tween-20 for 1 hour and washed
with the same blocking buffer 3 times. Fluorescently labeled
R12.69 was diluted to 100 nM in 90 𝜇L of 1x SB. It was then
added to each well and incubated at room temperature for
1 hour. Unbound R12.69 was then aspirated and followed
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by washing with 1x SB 5 times. Finally, 90 𝜇L of 1x SB
was added to each well and the fluorescence emission was
measured by a Synergy 2 microplate reader with excitation at
490 nm and emission at 520 nm (Biotek US; Winooski, VT).
Fluorescence measurements were normalized to 90 𝜇L of
100 nM fluorescent MRE in 1x SB as described previously [22].
Protein target sets were performed in triplicate and control
well sets in duplicate. All data was averaged and standard
deviations were calculated. A one-tailed 𝑡-test was performed
to determine the statistical significance in difference of the
means (𝑃 ≤ 0.05).
2.6. Toxin B-Specific MRE Modified ELISA Assays. Commercially synthesized 5 -amino-C6 modified R12.69 was used
as the toxin B capturing element in a modified sandwich
ELISA assay. First, 40 nM of 5 -amino-C6 modified R12.69
in immobilization buffer (100 mM sodium chloride, 20 mM
potassium phosphate, and 2 mM magnesium chloride, pH
7.56) was denatured at 95∘ C for 5 min and cooled to room
temperature. Then, 100 𝜇L of the ssDNA was added to
individual wells of a maleic anhydride activated plate (Pierce;
Rockford, IL, USA) and incubated overnight with shaking at
room temperature (500 RPM). Each well was then blocked
with 0.1% BSA in 1x SB for 1 hour and washed three times
with wash buffer containing 0.1% BSA, 0.05% Tween-20 in 1x
SB at room temperature to remove nonimmobilized ssDNA.
Normal human fecal samples (Lee Biosolutions; St. Louis,
MO, USA) were reconstituted in 1x SB at 1 g to 20 mL ratio
and then centrifuged at 5000 ×g for 10 minutes to collect
fecal solution. Toxin B was spiked into 100 𝜇L of prepared
fecal solution and 100 𝜇L of 1x SB, respectively, at a final
concentration of 50 nM and served as active testing samples.
Blank wells without immobilized ssDNA served as the first
negative control, and 100 𝜇L of 1x phosphate buffer solution,
100 𝜇L of 1x SB, and 100 𝜇L of fecal solution in wells with
immobilized ssDNA served as the second negative control.
All samples were added to individual wells and incubated for
1 hour with shaking at room temperature (500 RPM).
After sample incubation, wells were washed three times
with wash buffer to remove unbound toxin B. Then, 100 𝜇L
of chicken anti-toxin B primary antibody (List Biological
Laboratories; Campbell, CA, USA) at a 1 to 400 dilution ratio
in wash buffer was added to each well and incubated for
30 minutes at room temperature with shaking (500 PRM).
The primary antibody was then aspirated and each well was
washed three times as outlined above. A secondary goat
anti-chicken antibody conjugated to horseradish peroxidase
(Pierce; Rockford, IL, USA) at a 1 to 500 dilution ratio was
added and incubated for 30 minutes at room temperature
with shaking (500 RPM). Lastly, all contents were aspirated
and washed five times with wash buffer to remove nonspecifically bound antibodies (Figure 3). Additional negative
controls were wells without antibodies and wells with only
primary antibodies. Assays were performed in duplicate.
ABTS substrate (Pierce; Rockford, IL, USA) was added
to individual wells according to the manufacturer’s protocol.
Absorbance at 410 nm and 650 nm was measured in a Synergy
2 microplate reader using Gen5 1.06 software (Biotek US;
Winooski, VT, USA) in two-minute increments. All the data
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Figure 3: Illustration of the modified ELISA assay. The ssDNA MRE was used as the capturing element in the modified sandwich ELISA
assay and signal is amplified by using secondary antibody conjugated to horse radish peroxidase (HRP).

was averaged and standard deviations were calculated. A
two-tailed Student’s 𝑡-test was used to determine statistical
differences at 𝑃 < 0.05.

3. Results and Discussions
3.1. Identification of a Toxin B-Specific MRE. Twelve rounds
of SELEX were carried out to identify ssDNA MREs specific
to toxin B (Table 1). This SELEX scheme is designed to enrich
ssDNA MREs that bind to toxin B in solution and exclude
ssDNA molecules that bind to BSA, alpha toxin, exotoxin
A, and cholera toxin, which are likely to coexist in the
target environment. Multiple negative selection rounds were
performed to enhance the specificity of the ssDNA library.
After every three complete rounds of selection (rounds 3, 6, 9,
and 12), 30–80 random sequences were selected and analyzed.
In the round 12 ssDNA library, 43 sequences were
successfully obtained and analyzed. The largest superfamily
contained 17 sequences. All 17 sequences were further aligned
based on the common tetranucleotide sequence (CTAA)
and divided into five smaller subfamilies (Figure 4). It is
to be noted that one sequence R12.62 only contained TAA
trinucleotide; however it shared large homology within
the subfamily, and therefore it was also included in the
analysis. The CTAA tetranucleotide was not found in the
constant regions, and therefore the constant regions did not
participate in the family analysis and were omitted in the

figure presentation. However, previous studies showed that
the constant regions of the MRE sequence can be involved
in their functional secondary structures; thus they were
not ignored in the overall decision of choosing candidate
sequences [35–39]. Two sequences, R12.12 and R12.27, were
identical. However, the sequences were not chosen for further
characterization based on the relatively higher Gibbs free
energy value (Δ𝐺) (indicating lower stability) and multiple
possible secondary structures. Sequences R12.30, R12.66,
and R12.78 had the lowest Δ𝐺 values, but their variable
regions did not sufficiently participate in the formation of
stem-loop structures according to the Mfold predictions.
Only one sequence, R12.69, had one possible predicted
structure, with a relatively low Δ𝐺 value (−8.07 kcal/mol),
and sufficient stem-loop structures formed from the variable
region (Figure 5). Therefore, R12.69 was chosen for further
characterization.
3.2. Affinity and Specificity of Toxin B-Specific MRE. Surface
plasmon resonance was used to determine the affinity of
R12.69. Single cycle kinetics analysis was performed on both
home-made and commercial CM5 SPR sensor chips. This
type of assay was chosen instead of multicycle kinetics
because there was no need to predetermine the regeneration
condition of the sensor chip. This type of assay has also been
used in previous studies to determine the binding affinities
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Family 1
TGCTTTTAGAATCAGACTAACAGGTTTAT-GTCTG
TGCTTTTAGAATCAGACTAACAGGTTTAT-GTCTG
CTTACGGCTAAGATGTTTTTAGT-TCGGGGTTCTC

R12.12
R12.27
R12.39

R12.33
R12.13
R12.26
R12.30

Family 2
GATATTCGGTTATAAAGTCCTAATAT------AAAAGCCA
CCTGACGCTAAAGTCTGGTCAAAAGGCAACATTT
NCTCACATCTGACTGCGAAGGTAAGTCTAAG-TATA
CGTAGGCGGTATCTTGAGTCTAAACTTCAAGGA

Family 3
R12.06
CACCTAATGGGAAG-AGATGGCCTCCACGAA-GTT-T
R12.62
TAATGGGAGGTAGACTACCAAT-CGTT-GTTATTTG
R12.45 AATGGTAATGTCTGGACCATGCCTAATGC-AATCC
R12.43
GATCACTGGAA-TGGCCTAAATT-AAGACACAG-----TGC

R12.49
R12.66
R12.65
R12.69

R12.75
R12.78

Family 4
GGT-CCGGGAACTAAGCGTGGTACGTGA-----TTAATTG
GTTCAAACCGGTTGCAGCACCTAATAGTGC--------------AAT
TGATCTAATATCCGTGGATCGCGGGTTTAAGTTA
CCTCGCTAATGCTGCTTGATGTGTGGCCTCGAAT
Family 5
TTGGTACACCCCTTCGCTCGTCACTAA-ACCCAGG
CA--GTAGTGGT-GTGGCTAAGATCCTGGCGTATGC

ΔG (kcal/mol)
−6.83
−6.83
−5.94

Possible structures
8
8
3

Homology (%)
100 (34/34)
100 (34/34)
41 (14/34)

ΔG (kcal/mol)
−3.99
−7.61
−7.05
−9.73

Possible structures
5
4
3
1

Homology (%)
41 (14/34)
41 (14/34)
32 (11/34)
36 (12/33)

ΔG (kcal/mol)
−7.05
−5.47
−8.58
−8.27

Possible structures
3
6
3
2

Homology (%)
68 (23/34)
62 (21/34)
50 (17/34)
53 (18/34)

ΔG (kcal/mol)
−7.04
−9.92
−6.15
−8.07

Possible structures
3
1
4
1

Homology (%)
58 (30/34)
55 (18/33)
50 (17/34)
44 (15/34)

ΔG (kcal/mol)
−6.95
−9.88

Possible structures
2
1

Homology (%)
44 (15/34)
45 (15/33)

Figure 4: Sequence families of the round 12 library. Only the variable region is shown in the aligned subfamily of the CTAA superfamily. MRE
sequences are aligned to the CTAA tetranucleotide sequence. Highlighted regions represent sequence homology shared in the subfamilies.
Δ𝐺 represents the Gibbs free energy values. Possible structures indicate the number of predicted structures from the Mfold web server [33].
Percent homology is calculated from highlighted nucleotides divided by the length of the sequenced variable region.

Table 2: Cross binding reactivity of R12.69 ssDNA MRE.
Target

𝑃 value

Average fluorescence (RFU)

Standard deviation

Selectivity ratio

Toxin B

0.0176

0.0066

—

—

Cholera toxin

0.0080

0.0041

0.0497

2.2

Alpha toxin

0.0033

0.0022

0.0117

5.4

Exotoxin A

0.0037

0.0022

0.0130

4.7

Bovine serum albumin

0.0030

0.0018

0.0106

5.8

For each protein target, average fluorescence is given with standard deviation. The 𝑃 value is given from a 𝑡-test between toxin B and other negative targets.
The selective ratio describes the number of times greater binding to toxin B than to other negative targets.

of nucleic acid MREs [40, 41]. Two assays were performed
on CM5 sensor chip and one assay was performed on homemade sensor chip. There were negligible differences between
the equilibrium dissociation constants (𝐾𝑑 ) obtained from
both types of sensor chips. The average 𝐾𝑑 value from the
three assays was determined to be 47.3±13.7 nM (Figure 6). It
is to be noted that the MRE was immobilized covalently onto
the sensor chip surfaces, which was different than most of
the previous studies [40, 42–44]. The surfaces of both homemade and CM5 sensor chips were negatively charged under a
neutral to basic running buffer (IM buffer), and the electrical
repulsion between the negatively charged DNAs may lead
to variable levels of ligand immobilization and different
levels of maximum SPR response unit. However, analyte
and ligand binding was saturated in all three independent
assays (Figure 5), thus validating the use of covalent linkage

for MRE immobilization in SPR analysis. The determined
dissociation constant (𝐾𝑑 ) was comparable to other MREs
targeting bacterial toxins [34, 45, 46].
The cross binding activity of R12.69 was determined by
fluorescence plate assay. The ssDNA MRE preferably binds to
toxin B greater than other negative targets in the selection
scheme (Table 2). The binding of R12.69 to toxin B is 2.2
times higher than chorea toxin (𝑃 = 0.0497), 5.4 times
higher than alpha toxin (𝑃 = 0.0117), 4.7 times higher
than exotoxin A (𝑃 = 0.0130), and 5.8 times higher than
bovine serum albumin (𝑃 = 0.0106). It is to be noted
that both cholera toxin (84 kDa) and alpha toxin (33 kDa)
were introduced only once in the negative selection scheme
(Table 1). However, the selectivity over alpha toxin is more
than double that of cholera toxin. It is likely that the ssDNA
library was enriched to bind preferably to large globular
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Figure 5: Secondary structure and sequence of R12.69 ssDNA MRE. (a) ssDNA sequence of toxin B MRE R12.69. The red portions indicate
the constant regions for primer attachment, and the black portion indicates the variable region. (b) Mfold prediction of R12.69 secondary
structure. Highlighted sequence, CTAA, represents most common tetranucleotide sequence in the variable regions of the 43 sequences
obtained from the round 12 library, and it is used as the center for sequence alignment in Figure 4 [33].

This result validates that multiple negative targets and
the competitive elution strategy employed in our stringent
SELEX method can greatly enhance the specificity of ssDNA
MREs.

140
120
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20
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Figure 6: Affinity measurements of R12.69. A representative SPR
affinity saturation curve of R12.69 with 1 : 1 binding fit. The averaged
equilibrium dissociation constant and standard error of three SPR
measurements is 47.3 ± 13.7 nM.

protein targets (M.W. of toxin B = 270 kDa) during early selection rounds. Other negative targets were introduced multiple
times in the negative selection scheme and therefore their
respective cross binding activities were sufficiently decreased.

3.3. Diagnostic Application of Toxin B-Specific MRE. A modified sandwich ELISA assay was developed in this study to
investigate the translational potential of R12.69. Reproducible
detection of 50 nM toxin B spiked in human fecal solutions
was achieved compared to control in 8 minutes after HRP
substrate incubation (𝑃 < 0.05) (Figure 7). It is to be noted
that fecal matter is a complex matrix, which contains multiple macromolecules and ions [47]. Meanwhile, the threedimensional structure of nucleic MREs is highly dependent
on the temperature, pH, and ionic strength of the binding
condition and these structures are related to their binding
abilities [48]. This modified ELISA assay demonstrated the
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Figure 7: Modified ELISA assays of toxin B. Data from one modified sandwich ELISA assay with absorbance measured at OD 410 nm.
Absorbance levels presented are subtracted from background levels of blank wells without immobilized DNA (negative control). Error bars
represent 2x standard deviations of 2 sample replicates. (a) Statistical significance levels with respect to DNA in buffer background (without
toxin B) of 𝑃 < 0.01 are designated by ∗∗. (b) Statistical significance levels with respect to fecal background (without toxin B) of 𝑃 < 0.05 are
designated by ∗. Buffer: 1x selection buffer; feces: 1 g/20 mL 1x selection buffer.

robustness of R12.69 in complex biological matrices. Previous
studies have identified ssDNA MREs specific for bacterial
toxins and similar ELISA assays were developed for toxin
detection [34, 49]. However, both ELISA detections were not
tested in clinically relevant samples, which is necessary for
translation. Recently, slow off-rate modified binding elements
(SOMAmer by SomaLogic, Inc.; Boulder, CO, USA) specific
for toxins B and A and binary toxin of C. difficile have been
identified with subnanomolar affinities [50]. The authors
also reported sensitive detection of toxin B at picomolar
concentrations in multiple assays, though fecal preparations
were not tested in all of the assays. A previous study reported
that fecal toxin B levels in patients with CDI ranged from
approximately 26 ng/mL to 25 𝜇g/mL [51]. The current MRE
modified ELISA assay can detect toxin B level at 50 nM
(1.35 𝜇g/mL), that is, within a clinically relevant concentration.
Currently, multiple commercial toxin B ELISA diagnostic
kits are available in the market and offer sensitive detection
of toxin B at nanograms/mL concentrations. It is to be noted
that the current clinical usage of the unmodified ssDNA
MRE identified in this study is limited due to its lower
sensitivity. However, ssDNA MREs have several advantages
over antibodies, such as inexpensive chemical synthesis and
reusability [52]. The use of the toxin B-specific MRE in the
modified sandwich ELISA assay therefore has a cost advantage over other currently available diagnostic techniques and
may offer an option for rapid initial screening of CDI. This
MRE may also be incorporated into an SPR biosensor for
real-time, label-free toxin B detection in biological matrices
[42, 44]. It is also possible to increase the stability of the MRE
through chemical modification to bases of DNA and that may
stabilize its secondary structure in complex matrices [53].
Overall, the use of R12.69 demonstrated a proof of concept
in substituting antibody as the antigen capturing element
in clinically relevant samples and may have the potential to
augment current and emerging diagnostic techniques of C.
difficile infections.

4. Conclusions
A ssDNA molecular recognition element specific for toxin
B has been identified with nanomolar affinity after twelve
rounds of selection and is highly specific toward the target
of interest. It also showed sensitive detection of toxin B in
human fecal sample through a modified sandwich ELISA
assay and demonstrated a proof-of-concept diagnostic application of the ssDNA MRE.
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“Correlation of disease severity with fecal toxin levels in patients
with Clostridium difficile-associated diarrhea and distribution
of PCR ribotypes and toxin yields in vitro of corresponding
isolates,” Journal of Clinical Microbiology, vol. 44, no. 2, pp. 353–
358, 2006.

Journal of Nucleic Acids
[52] K. M. You, S. H. Lee, A. Im, and S. B. Lee, “Aptamers as
functional nucleic acids: in vitro selection and biotechnological
applications,” Biotechnology and Bioprocess Engineering, vol. 8,
no. 2, pp. 64–75, 2003.
[53] R. E. Wang, H. Wu, Y. Niu, and J. Cai, “Improving the stability
of aptamers by chemical modification,” Current Medicinal
Chemistry, vol. 18, no. 27, pp. 4126–4138, 2011.
[54] D. J. Reinert, T. Jank, K. Aktories, and G. E. Schulz, “Structural
basis for the function of Clostridium difficile toxin B,” Journal of
Molecular Biology, vol. 351, no. 5, pp. 973–981, 2005.
[55] J. E. Wedekind, C. B. Trame, M. Dorywalska et al., “Refined
crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of
toxicity,” Journal of Molecular Biology, vol. 314, no. 4, pp. 823–
837, 2001.
[56] A. Bujacz, “Structures of bovine, equine and leporine serum
albumin,” Acta Crystallographica Section D: Biological Crystallography, vol. 68, part 10, pp. 1278–1289, 2012.
[57] C. J. O’Neal, M. G. Jobling, R. K. Holmes, and W. G. J. Hol,
“Structural basis for the activation of cholera toxin by human
ARF6-GTP,” Science, vol. 309, no. 5737, pp. 1093–1096, 2005.
[58] Y. Tanaka, N. Hirano, J. Kaneko, Y. Kamio, M. Yao, and I.
Tanaka, “2-Methyl-2,4-pentanediol induces spontaneous assembly of staphylococcal 𝛼-hemolysin into heptameric pore
structure,” Protein Science, vol. 20, no. 2, pp. 448–456, 2011.

International Journal of

Peptides

BioMed
Research International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Advances in

Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com

International Journal of

Genomics

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Journal of

Nucleic Acids

Zoology

International Journal of

Hindawi Publishing Corporation
http://www.hindawi.com

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Volume 2014

Submit your manuscripts at
http://www.hindawi.com
The Scientific
World Journal

Journal of

Signal Transduction
Hindawi Publishing Corporation
http://www.hindawi.com

Genetics
Research International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Anatomy
Research International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Enzyme
Research

Archaea
Hindawi Publishing Corporation
http://www.hindawi.com

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Biochemistry
Research International

International Journal of

Microbiology
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

International Journal of

Evolutionary Biology
Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Molecular Biology
International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Advances in

Bioinformatics
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Journal of

Marine Biology
Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

